Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Vitrolife AB (publ) (VITR.ST)
Gothenburg, SE
Vitrolife AB (publ) is a medical technology company specializing in the development, production, and global sale of products for assisted reproduction. Their comprehensive offering includes a variety of essential tools for fertility treatments, such as oocyte retrieval needles, sperm processing solutions, specialized in vitro fertilization media and oils, and micromanipulation pipettes. The company also provides general labware, incubators, cryopreservation products, and systems for preimplantation genetic testing. Furthermore, Vitrolife delivers advanced equipment, including the EmbryoScope and Primo Vision time-lapse systems, along with dedicated dishes and evaluation software for these platforms. Their technology portfolio extends to Octax laser and imaging systems, as well as environmental monitoring solutions like log and guard systems and wireless sensors. With its headquarters located in Gothenburg, Sweden, Vitrolife maintains a significant international presence, operating across Europe, the Middle East, and Africa; Asia; Japan and the Pacific; and both North and South America. Founded in 1994, the company was initially known as Scandinavian IVF Science before officially changing its name to Vitrolife AB (publ) in 1998.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.98% | -7.83% | -5.54% | +3.67% | -32.31% | -25.64% | -35.70% | -53.70% | -70.98% | +15.40% | +1,292.96% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | -1 |
| Buy | 4 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%-4.7% Q1'26: -4.2% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%-1,079.1% Q1'26: +0.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%-144.0% Q1'26: +15.9% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%-140.6% Q1'26: +18.5% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%-55.2% Q1'26: +5.3% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%-0.1% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-0.38× Q1'26: 1.89× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 3 EPS Ana. |
Dec 2027 5 Rev. Ana. 3 EPS Ana. |
Dec 2028 5 Rev. Ana. 4 EPS Ana. |
Dec 2029 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
722.37M
est: 703.52M (+2.7%)
|
856.11M
est: 847.57M (+1.0%)
|
1.05B
est: 1.07B (-2.2%)
|
1.15B
est: 1.14B (+1.4%)
|
1.48B
est: 1.47B (+0.6%)
|
1.25B
est: 1.25B (-0.2%)
|
1.68B
est: 1.66B (+1.5%)
|
3.23B
est: 3.21B (+0.8%)
|
3.51B
est: 3.54B (-0.7%)
|
3.61B
est: 3.60B (+0.4%)
|
3.44B
est: 3.44B (-0.1%)
|
3.49B
3.43B – 3.54B
+1.2% YoY
|
3.75B
3.68B – 3.80B
+7.6% YoY
|
4.04B
4.03B – 4.06B
+7.8% YoY
|
4.27B
4.20B – 4.34B
+5.7% YoY
|
| EBITDA |
281.12M
est: 43.50M (+546.2%)
|
303.77M
est: 52.41M (+479.6%)
|
407.85M
est: 66.13M (+516.8%)
|
450.67M
est: 70.22M (+541.8%)
|
594.40M
est: 91.00M (+553.1%)
|
438.65M
est: 77.18M (+468.3%)
|
579.60M
est: 102.40M (+466.0%)
|
977.00M
est: 198.36M (+392.5%)
|
-3.19B
est: -737.40M (-331.9%)
|
783.00M
est: -749.93M (+204.4%)
|
-4.41B
est: -718.37M (-513.6%)
|
-726.98M
-739.26M – -716.06M
-1.2% YoY
|
-781.98M
-792.05M – -767.93M
-7.6% YoY
|
-843.13M
-846.26M – -840.00M
-7.8% YoY
|
-891.24M
-904.44M – -876.49M
-5.7% YoY
|
| EBIT |
228.03M
est: -21.13M (+1,179.3%)
|
249.73M
est: -25.45M (+1,081.2%)
|
341.38M
est: -32.12M (+1,163.0%)
|
399.08M
est: -34.10M (+1,270.2%)
|
495.01M
est: -44.20M (+1,220.0%)
|
368.28M
est: -37.48M (+1,082.5%)
|
470.69M
est: -49.73M (+1,046.4%)
|
581.00M
est: -96.33M (+703.1%)
|
-3.61B
est: -1.02B (-253.2%)
|
783.00M
est: -1.04B (+175.3%)
|
-4.84B
est: -995.82M (-385.5%)
|
-1.01B
-1.02B – -992.61M
-1.2% YoY
|
-1.08B
-1.10B – -1.06B
-7.6% YoY
|
-1.17B
-1.17B – -1.16B
-7.8% YoY
|
-1.24B
-1.25B – -1.22B
-5.7% YoY
|
| Net Income |
182.85M
est: 202.25M (-9.6%)
|
190.37M
est: 237.31M (-19.8%)
|
263.64M
est: 351.54M (-25.0%)
|
309.70M
est: 403.37M (-23.2%)
|
382.79M
est: 496.19M (-22.9%)
|
286.85M
est: 368.07M (-22.1%)
|
341.00M
est: 396.23M (-13.9%)
|
394.00M
est: 514.04M (-23.4%)
|
-3.85B
est: -3.80B (-1.4%)
|
513.00M
est: 531.34M (-3.5%)
|
-5.01B
est: 474.46M (-1,156.6%)
|
491.25M
449.91M – 735.89M
+3.5% YoY
|
609.71M
554.34M – 876.06M
+24.1% YoY
|
708.18M
707.83M – 861.66M
+16.2% YoY
|
846.39M
828.18M – 862.69M
+19.5% YoY
|
| SGA |
220.33M
est: 213.72M (+3.1%)
|
249.83M
est: 257.48M (-3.0%)
|
269.61M
est: 324.88M (-17.0%)
|
283.81M
est: 345.00M (-17.7%)
|
350.96M
est: 447.10M (-21.5%)
|
311.35M
est: 379.19M (-17.9%)
|
503.74M
est: 503.10M (+0.1%)
|
1.00B
est: 974.51M (+2.8%)
|
1.12B
est: 1.11B (+0.9%)
|
1.23B
est: 1.13B (+9.4%)
|
1.02B
est: 1.08B (-5.2%)
|
1.09B
1.08B – 1.11B
+1.2% YoY
|
1.17B
1.15B – 1.19B
+7.6% YoY
|
1.27B
1.26B – 1.27B
+7.8% YoY
|
1.34B
1.32B – 1.36B
+5.7% YoY
|
| EPS |
1.68
est: 1.49 (+12.6%)
|
1.75
est: 1.75 (-0.1%)
|
2.43
est: 2.59 (-6.3%)
|
2.85
est: 2.98 (-4.2%)
|
3.53
est: 3.66 (-3.6%)
|
2.64
est: 2.72 (-2.8%)
|
2.97
est: 2.92 (+1.6%)
|
2.91
est: 3.79 (-23.3%)
|
-28.44
est: -28.06 (-1.4%)
|
3.79
est: 3.93 (-3.5%)
|
-37.01
est: 3.51 (-1,155.2%)
|
4.39
3.32 – 5.43
+25.3% YoY
|
5.24
4.09 – 6.47
+19.3% YoY
|
5.65
5.23 – 6.36
+7.7% YoY
|
6.25
6.12 – 6.37
+10.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-26 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-25 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-19 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-18 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-15 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-13 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-12 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-11 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-08 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-07 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-05 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-04 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares MSCI Europe Small-Cap ETF IEUS | 0.04% | 75.3K | 0.41% |
| 2 | Xtrackers MSCI Europe Small Cap UCITS ETF 1C XXSC.L | 0.04% | 1.45M | 0.30% |
| 3 | Dimensional - International Small Cap Value ETF DISV | 0.03% | 1.55M | 0.42% |
| 4 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Acc CEM.PA | 0.03% | 104.9K | 0.23% |
| 5 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Dist X026.DE | 0.03% | 104.9K | 0.23% |
| 6 | iShares International Small-Cap Equity Factor ETF ISCF | 0.03% | 176.8K | 0.24% |
| 7 | Schwab International Small-Cap Equity ETF SCHC | 0.03% | 1.41M | 0.06% |
| 8 | State Street SPDR S&P International Small Cap ETF GWX | 0.02% | 209.1K | 0.40% |
| 9 | State Street SPDR MSCI Europe Small Cap Value Weighted UCITS ETF EUR Acc ZPRX.DE | 0.02% | 161.0K | 0.30% |
| 10 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.02% | 2.90M | 0.06% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bronwyn Brophy | Chief Executive Officer & President | 17M | female |
| Claus Bisgaard | Senior Vice President of Technologies | — | male |
| Erin Schardt | Senior VP & GM of North America | — | female |
| Ermanno Sironi | Chief Operating Officer | — | male |
| Jessica Jonasson | Chief HR Officer | — | female |
| Marcos Jose Fernandez | Vice President Strategy, Sustainability & Corporate Development | — | — |
| Meishan Jin | Senior Vice President & GM of China | — | — |
| Olivia Natens | Senior Vice President of Sales & Marketing | — | — |
| Par Ihrskog | Chief Financial Officer | — | male |
| Ricardo Capella | Senior Vice President Genetic Services | — | — |
| Rickard Ericsson | Senior Vice President Innovation | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for VITR.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
